Quick Answer
Adaptive Biotechnologies Corp reported Total Revenue of $276.98 million for fiscal year 2025.
Adaptive Biotechnologies Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $276.98M +54.8% |
$178.96M +5.1% |
$170.28M -8.1% |
$185.31M +20.1% |
$154.34M +56.9% |
$98.38M +15.6% |
| Revenue (ASC 606) | $276.98M +54.8% |
$178.96M +5.1% |
$170.28M -8.1% |
$185.31M +20.1% |
$154.34M +56.9% |
$98.38M +15.6% |
| Net Income | -$59.50M +62.7% |
-$159.49M +29.2% |
-$225.25M -12.5% |
-$200.19M +3.4% |
-$207.28M -41.8% |
-$146.23M -113.1% |
| Diluted EPS | -$0.39 +63.9% |
-$1.08 +30.8% |
-$1.56 -11.4% |
-$1.40 +5.4% |
-$1.48 -33.3% |
-$1.11 |
| Total Assets | $512.74M -4.9% |
$539.38M -18.4% |
$661.13M -22.8% |
$856.62M -7.2% |
$923.34M -17.3% |
$1.12B +22.4% |
| Cash and Equivalents | $70.50M +47.1% |
$47.92M -26.3% |
$65.06M -27.7% |
$90.03M -35.3% |
$139.06M +12.7% |
$123.44M +27.8% |
| Long-Term Debt | $126.57M -4.4% |
$132.41M +1.3% |
$130.66M +4.2% |
$125.36M | — | — |
| Stockholders Equity | $218.79M +7.9% |
$202.71M -34.3% |
$308.40M -33.6% |
$464.17M -23.2% |
$603.99M -18.7% |
$743.27M +30.2% |
| R&D Expense | $93.77M -8.9% |
$102.95M -15.7% |
$122.12M -13.9% |
$141.76M -0.4% |
$142.34M +22.6% |
$116.07M +64.2% |
| Operating Income | -$57.12M +64.9% |
-$162.55M +28.4% |
-$227.03M -13.4% |
-$200.19M +4.2% |
-$208.97M -36.7% |
-$152.82M -94.9% |
| Shares Outstanding | 153.78M +4.1% |
147.77M +1.9% |
145.08M +1.4% |
143.11M +1.2% |
141.39M +2.7% |
137.65M +9.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $93.97M | +102.4% | +59.6% |
| Revenue (ASC 606) | September 30, 2025 | $93.97M | +102.4% | +59.6% |
| Net Income | September 30, 2025 | $9.55M | +129.8% | +137.3% |
| Diluted EPS | September 30, 2025 | $0.06 | +127.3% | +135.3% |
| Total Assets | September 30, 2025 | $490.61M | -12.2% | -1.2% |
| Cash and Equivalents | September 30, 2025 | $55.03M | +44.5% | +27.5% |
| Long-Term Debt | September 30, 2025 | $129.41M | -2.5% | -0.8% |
| Stockholders Equity | September 30, 2025 | $204.44M | -8.6% | +13.8% |
| R&D Expense | September 30, 2025 | $23.67M | -2.0% | -1.9% |
| Operating Income | September 30, 2025 | $10.29M | +131.5% | +141.1% |
| Shares Outstanding | September 30, 2025 | 152.58M | +3.4% | +0.2% |
- Adaptive Biotechnologies Corp reported Total Revenue of $276.98 million for fiscal year 2025.
- Adaptive Biotechnologies Corp showed an increase of +54.8% in Total Revenue compared to the prior fiscal year.
- Adaptive Biotechnologies Corp reported Revenue (ASC 606) of $276.98 million for fiscal year 2025.
- Adaptive Biotechnologies Corp showed an increase of +54.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Adaptive Biotechnologies Corp reported Net Income of -$59.50 million for fiscal year 2025.
- Adaptive Biotechnologies Corp showed an increase of +62.7% in Net Income compared to the prior fiscal year.
- Adaptive Biotechnologies Corp reported Diluted EPS of $0.39 per share (loss) for fiscal year 2025.
- Adaptive Biotechnologies Corp showed an increase of +63.9% in Diluted EPS compared to the prior fiscal year.
- Adaptive Biotechnologies Corp reported Total Assets of $512.74 million for fiscal year 2025.
- Adaptive Biotechnologies Corp showed a decrease of -4.9% in Total Assets compared to the prior fiscal year.
- Adaptive Biotechnologies Corp reported Cash and Equivalents of $70.50 million for fiscal year 2025.
- Adaptive Biotechnologies Corp showed an increase of +47.1% in Cash and Equivalents compared to the prior fiscal year.
- Adaptive Biotechnologies Corp reported Long-Term Debt of $126.57 million for fiscal year 2025.
- Adaptive Biotechnologies Corp showed a decrease of -4.4% in Long-Term Debt compared to the prior fiscal year.
- Adaptive Biotechnologies Corp reported Stockholders Equity of $218.79 million for fiscal year 2025.
- Adaptive Biotechnologies Corp showed an increase of +7.9% in Stockholders Equity compared to the prior fiscal year.
- Adaptive Biotechnologies Corp reported R&D Expense of $93.77 million for fiscal year 2025.
- Adaptive Biotechnologies Corp showed a decrease of -8.9% in R&D Expense compared to the prior fiscal year.
- Adaptive Biotechnologies Corp reported Operating Income of -$57.12 million for fiscal year 2025.
- Adaptive Biotechnologies Corp showed an increase of +64.9% in Operating Income compared to the prior fiscal year.
- Adaptive Biotechnologies Corp reported Shares Outstanding of 153.78 million shares for fiscal year 2025.
- Adaptive Biotechnologies Corp showed an increase of +4.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: